Methods. 625 morbidly obese pts undergoing bariatric surgery (Bariatric-cohort:BC) and 369 non-morbidly obese pts referred for NAFLD to a liver center (Hepato-cohort:HC), from the same urban area were studied during the same period. Other liver diseases
were excluded. Liver biopsies were read using the FLIP algorithm and the SAF score. Advanced fibrosis (AF) was defined as bridging fibrosis or cirrhosis. BC and HC were compared according to steatosis grade, glycemic status and insulin resistance (IR). A case-control study with a 1:1 random selection of age and sex-matched patients from the two cohorts MK0683 chemical structure was performed. Results. Both AF and NASH were more prevalent in the HC than in the BC (22%vs.7%,p<0.001 and 42%vs.35%,p=0.019, respectively). BC pts had more pre-dia-betes/diabetes (58%vs.48%,p=0.002) and higher HOMA-IR (7.3±22.9vs.4.2±3.9,p<0.001) than HC pts while the latter were older (53±12vs.43±12
yrs,p<0.001), more frequently male (64%vs.20%,p<0.001), with dyslipidemia and higher ALT (67±40 vs. 35±27, p<0.001). 14% of HC and 21% of BC had grade 0 steatosis (p<0.01) but grades 1 to 3 steatosis were distributed similarly. The higher prevalence of AF in the HC persisted after adjustment for steatosis grade, glycemic status and HOMA-IR. After matching 230 HC and 230 BC pts for age and sex, the difference in AF persisted (22% vs. 12%, respectively, p=0.003), even in the subgroup of patients with pre-diabetes/diabetes (33% vs. 14%, p<0.001). The association MCE公司 between HC (vs. BC) and AF was independent of age, sex, BMI, metabolic factors, HOMA-IR and ALT with Tamoxifen nmr an odds ratio of 3.36 (1.31-8.60) in the whole cohorts and 4.91 (1.50-16.39) in
the age and sex-matched cohorts. In contrast, the prevalence of NASH was similar in the matched cohorts (45%) and HC was not independently associated with the presence of NASH. Conclusion. Despite having a similar age and sex-adjusted prevalence of NASH, morbidly obese pts undergoing bariatric surgery have less severe fibrotic liver disease than non-morbidly obese pts seen in hepatology units. Differences in age, sex and metabolic profile do not account for this higher fibrotic risk in hepatology pts. Future studies are needed to understand the more severe liver damage in pts with overweight/moderate obesity or the protective effect seen in morbidly obese pts. Disclosures: Thierry Poynard – Advisory Committees or Review Panels: MSD; Grant/Research Support: BMS; Stock Shareholder: Biopredictive Vlad Ratziu – Advisory Committees or Review Panels: GalMed, Abbott, Genfit, Enterome, Gilead; Consulting: Astellas, Axcan, Pfizer, Sanofi-Synthelabo, Genen-tech, Nycomed The following people have nothing to disclose: Fabio Nascimbeni, Judith Aron-Wisnewsky, Pierre Bedossa, Joan Tordjman, Raluca Pais, Karine Clément Purpose: The incidence of NASH is rising and is highly associated with metabolic syndrome and increased mortality.